PRODUCT MONOGRAPH Prolia Pr (denosumab)

First Page		Document Content
$Amgen / Denosumab / Bisphosphonates / Drugs / Osteoporosis / Osteonecrosis of the jaw / Aromatase inhibitor / Hypovitaminosis D / Hip fracture / Medicine / Health / Pharmacology$ Date: 2014-07-03 07:23:15 Amgen Denosumab Bisphosphonates Drugs Osteoporosis Osteonecrosis of the jaw Aromatase inhibitor Hypovitaminosis D Hip fracture Medicine Health Pharmacology		PRODUCT MONOGRAPH Prolia Pr (denosumab) Add to Reading List Source URL: www.amgen.ca Download Document from Source Website File Size: 643,66 KB Share Document on Facebook

	Preventing Falls * Persons with developmental disabilities may be at increased risk for falls due to things such as cerebral palsy, osteoporosis, epilepsy and some medications. DocID: 1vgLN - View Document
	NEWS RELEASE NEWS RELEASE NEWS RELEASE NEWS RELEASE NEWS RELEASE Contact: (SUNSWEET GROWERS TO RETURN AS OFFICIAL SPONSOR OF WORLD OSTEOPOROSIS DAY Sunsweet Promotes the Positive Role o DocID: 1vd0S - View Document
	Master’s Thesis Proposal Damage Morphology in Compact Bone Associated with Distinct Loading Modes Background An annual prevalence of 1.6 million osteoporosis related hip fractures, constitutes a major sociomedical cha DocID: 1v0QH - View Document
	Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle® (Estradiol Transdermal System) Minivelle now approved for prevention of postmenopausal osteoporosis at all doses Newmg/day Minivelle, DocID: 1ufoU - View Document
	New Minivelle® (Estradiol Transdermal Systemmg/day Dose Now Available by Prescription in U.S. Pharmacies New dose approved by FDA for the prevention of postmenopausal osteoporosis only; higher doses of Minivelle DocID: 1u26h - View Document